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ABSTRACT 
Flupirtine is an amino pyridine derivative that functions as a centrally acting non-opioid, non-steroidal analgesic. It is a selective 
neuronal potassium channel opener that also has NMDA receptor antagonist properties. Its muscle relaxant properties make it 
popular for back pain and other orthopedics uses. In the present investigation, recently developed mixed hydrotropic solid dispersion 
technology precludes the use of organic solvent and also decreases the individual concentration of hydrotropic agents, 
simultaneously decreasing their toxic potential. Mixed-hydrotropic solubilisation technique is the experience to increase the 
solubility of poorly water soluble drugs in the aqueous solution containing blends of hydrotropic agents, which may give synergistic 
enhancement effect on solubility of poorly water-soluble drugs and to reduce concentrations of each individual hydrotropic agent to 
minimize their toxic effects due to high concentration of hydrotropic agents. The Flupirtine loaded solid dispersion was prepared by 
a solvent evaporation technique using sodium benzoate and a niacinamide hydrotropic mixture. The prepared solid dispersions were 
valuated regarding their solubility, mean particle size, in-vitro drug release. The prepared solid dispersions were found very stable 
(chemically). The superior dissolution rate due to its reduced particle size may have contributed to the increased oral bioavailability. 
This study demonstrated that mixed-solvency may be an alternative approach for poorly soluble drugs to improve their solubility and 
oral bioavailability. 
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INTRODUCTION 
Poor aqueous solubility as well high intra- and inter 
subject inconsistency are considered to be main 
barricades for poor oral bioavailability. A number of 
formulation approaches, such as solid dispersions, salt 
formation, micronization, cyclodextrin complexation, 
micellar solutions, nanoparticulates to improve the oral 
absorption of drugs
1, 2
. Hydrotropy is one of the 
recognized techniques available to enhance the aqueous 
solubility of a drug. It has a well-known impending of 
improving the solubilities and dissolution profiles of 
hydrophobic drugs
3, 4
. It is an another approach for the 
delivery of drugs, which is attached with drugs having a 
low water solubility and poor oral 
bioavailability
5
.Hydrotropy is a molecular occurrence, 
where by adding a second solute (hydrotrope) helps to 
increase the aqueous solubility of poorly soluble solutes. 
Simply the existence of a large quantity of one solute 
enhances the solubility of another solute 
6, 7
. Hydrotropes 
have an amphiphilic molecular structure, which contains 
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both hydrophilic and a hydrophobic portions. The 
competence of hydrotropic solubilization depends on the 
balance between the hydrophobic and hydrophilic 
fractions
8, 9
. Different association patterns of hydrotrope 
assemblies and unique geometrical features distinguish 
them from other solubilizers
10
. Improvement in the 
aqueous solubility by a hydrotrope is based on the 
molecular self-association of the hydrotrope with solute 
molecules
11
. Solid dispersion technology is one of the 
methods of increasing the dissolution rate and therefore 
the rate of absorption or total bioavailability of poorly 
water-soluble drugs. The common methods of making 
solid dispersions are solvent evaporation, fusion, and 
fusion-solvent methods
12-14
.  Flupirtine, ethyl-N-[2-
amino-6-(4-fluoro-phenylmethyl-amino) pyridine-3-yl] 
carbamate, is a non-opioid analgesic without antipyretic 
or antiphlogistic properties. It acts centrally on γ-
aminobutyric acid a receptors and the selective neuronal 
Kv7 potassium channel
15-17
, thus offering a mechanism-
based therapy for pain relief and normalization of 
muscle tension. In patients with acute and chronic pain, 
flupirtine is clinically as efficient as weak opioids and 
NSAIDs 
18-21
, and its well-known neuro protective 
properties make this drug a possible candidate for the 
treatment of Alzheimer’s, Creutzfeldt–Jakob’s and 
Parkinson’s,  disease and other neurodegenerative 
disorders 
22-25
. 
The objective of the present study was to formulate and 
evaluate flupirtine containing solid dispersion. A sodium 
benzoate and niacinamide hydrotropic mixture was 
utilized. 
MATERIALS AND METHODS 
Materials: 
Flupirtine Maleate was obtained as a gift sample from 
ZCL Chemical Limited Ankleshwar, India Sodium 
benzoate, sodium acetate; sodium citrate, urea and 
niacinamide were purchased from Sigma-Aldrich 
(Mumbai, India). All other chemicals and reagents used 
were of analytical grade. Double distilled water was 
prepared freshly and used whenever required. 
Method:  
Solubility study: 
An excess quantity flupirtine of was added to screw 
capped 10.0 mL glass vials containing the different 
aqueous systems composed of distilled water and 
various hydrotropic solutions of different concentrations 
in water. The resultant mixture was shaken vigorously 
for10.0 min and stirred on a magnetic stirrer plate at 
room temperature for 12 h. After the 12 h period 
elapsed, samples were withdrawn and centrifuged at 
10,000 RPM for 15.0 min. The supernatant of each batch 
was filtered through 0.45µm membrane filters. The 
filtrates were suitably diluted and analysed using a UV 
spectrophotometer (Systronics 2202 India) at 304 nm. 
The results of triplicate measurements and their means 
were reported. 
Preparation of solid dispersions by a mixed solvency 
approach: 
The solid dispersion of flupirtine was prepared with 
hydrotropic agent using a solvent evaporation technique. 
Concisely, different amounts of hydrotropic agents 
{sodium benzoate (5 gm) and niacinamide (5 gm.)} 
were suspended in 50 mL of aqueous flupirtine (2.5 g) 
solution. After the addition of hydrotropic agents, the 
resultant mixture was subjected to evaporation (wet). 
The wet product obtained from the evaporation step was 
dried in an oven set at 50 ± 2◦C to remove any 
remaining moisture. The resultant solid dispersions were 
passed through a #100 mesh. The prepared solid 
dispersions were stored in desiccators until their further 
evaluation. The physical mixtures were prepared in same 
the ratio triturating the drug and hydrotropic agent in a 
porcelain mortar. The physical mixtures were passed 
through a #100 mesh and stored in an air tight glass 
bottle until their further evaluation. The compositions of 
the solid dispersion and physical mixtures are given in 
Table 1 & 2. 
Table 1: Composition of solid dispersions of flupirtine maleate 
S. no. 
Solid dispersion  
Drug: solubilizers 
Quantity taken (gm) 
 FM SB NM SCI ST 
1 SDA 1:4 2.5 5 2.5 2.5 - 
2 SDB 1:3.33 2.4   4.0 2.0 2.0 - 
3 SDC 1:3 1.6 2.4 - - 2.4 
4 SDD 1:2 2.4 3.2 1.6 - - 
5 SDE 1:3 3.2 4.8 4.8 - - 
FM= Flupirtine maleate; SB= Sodium benzoate; NM= Niacinamide; SCI= Sodium citrate; ST= PEG 6000. 
 
Table 2: Composition of physical mixtures of flupirtine maleate 
S. No. 
Physical  mixture 
Drug: solubilizers 
Quantity taken (gm) 
 FM SB NM SCI ST 
1 PMA 1:4 2.5 5 2.5 2.5 - 
2 PMB 1:3.33 2.4   4.0 2.0 2.0 - 
3 PMC 1:3 1.6 2.4 - - 2.4 
4 PMD 1:2 2.4 3.2 1.6 - - 
5 PME 1:3 3.2 4.8 4.8 - - 
FM= Flupirtine maleate; SB= Sodium benzoate; NM= Niacinamide; SC= Sodium citrate; ST= PEG6000. 
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Characterization of the Prepared Solid Dispersion: 
Drug content and percentage yield: 
The drug contents and percentage yields of the solid 
dispersion and physical mixtures were determined. The 
samples were dissolved in a suitable quantity of distilled 
water and the drug content was determined by a UV 
spectrophotometer (Systronics 2202 India) at 304 nm. 
In-vitro dissolution study: 
The in-vitro dissolution studies were performed to 
conclude the rates of dissolution of the drug alone, solid 
dispersion and physical mixtures. The dose equivalent to 
100.0 mg was used for the dissolution study. The 
dissolution test was executed in an U.S.P. XXIV (type 
II) dissolution test apparatus (Model TDT6P, Electrolab 
Mumbai, India) with paddle to rotate at 50 r.p.m using 
900.0 mL of demineralised water was taken as 
dissolution medium. The temperature of the medium 
was kept at 37 ± 0.5◦C throughout the experiment. A 10 
mL aliquot was withdrawn at predetermined time 
intervals of 2, 5, 10, 15, 30, 45 and 60 min and filtered 
through 0.45 µm filters. Then, 10 mL of fresh 
dissolution medium was replaced to maintain the 
constant volume of dissolution medium. The filtrates 
were analysed using a UV spectrophotometer 
(Systronics 2202 India) at 304 nm. The results of 
triplicate measurements and their means were reported. 
Micromeritic Properties of Solid Dispersions: 
Bulk density: 
 It is defined as the mass of many particles of the 
material divided by the total volume they occupy. The 
total volume includes particle volume, inter-particle void 
volume, and internal pore volume. The bulk density of 
the formulated granules was evaluated using bulk 
density apparatus. It is expressed in gm/ml and is given 
by 
              
                  
                              
 
Tapped density: 
 It is the ratio of total mass of powder to the tapped 
volume of powder. The tapped volume was measured by 
tapping the powder to constant volume. It is expressed in 
gm/ml and is given by: 
                
                  
                            
 
Compressibility index and hausner ratio: 
 The compressibility index and hausner’s ratio are 
measures of the propensity of a powder to be 
compressed and the flow ability of granule. Carr’s index 
and Hausner’s ratio were calculated using following 
formula: 
                   
                           
              
 
                 
              
            
 
 
Angle of repose: 
 Angle of repose was determined by Neumann’s method 
and calculated using the formula, for un lubricated as 
well as lubricated granules. 
Tanθ=h/r 
θ=tan-1h/r 
Powder X-ray diffraction studies: 
X-ray powder diffraction (XRD) is a rapid analytical 
technique primarily used for phase identification of a 
crystalline material and can provide information on unit 
cell dimensions. The analyzed material is finely ground, 
homogenized and average bulk composition is 
determined. X-ray powder diffraction is most widely 
used for the identification of unknown crystalline 
materials (e.g. minerals, inorganic compounds).  
Differential scanning calorimetry: 
DSC is a thermo-analytical technique in which the 
differences in the amount of heat required to increase the 
temperature of a sample and reference are measured as a 
function of temperature. DSC can be used to measure a 
number of characteristic properties of a sample. Using 
this technique it is possible to observe fusion and 
crystallization events as well as glass 
transition temperatures. DSC can also be used to 
study oxidation, as well as other chemical reactions. 
Fourier transforms infrared spectroscopy: 
Fourier transform infrared spectroscopy (JASCO, FTIR-
4100, Japan) spectra of the drug alone, solid dispersion 
and physical mixtures were observed. Approximately 1–
2 mg of flupirtine, solid dispersion and physical 
mixtures were mixed with dry potassium bromide, and 
the samples were examined in a transmission mode over 
a wave number range of 4000 to 400 cm−1. Jasco 
spectramanager Ver. 2 (Japan) was used for data 
acquisition and analysis 
RESULTS AND DISCUSSION 
Then the solubility of the drug in distilled water was 
found in order to understand the extent to which the drug 
needs solubility enhancement. So, upon determination of 
solubility of drug through equilibrium method the 
solubility of drug in water was found to be 0.127%. The 
partition coefficient of the drug was also calculated 
using a mixture of water and octanol. The log of 
partition coefficient was found to be 3.2 indicating high 
hydrophobicity of the drug. Melting point of the drug 
was calculated through melting point apparatus. A small 
amount of the drug was added into a capillary tube that 
was blocked from side and an opening at the other that 
allowed the filling of the drug into capillary. 
Thermometer was placed to the adjacent of the capillary 
tube in order to note down the right temperature of 
melting. The drug powder started to melt at 174° C. 
Standard curve of flupirtine maleate: 
The UV spectrum of the drug in the range of 200-400nm 
on UV-visible spectrophotometer revealed that 
wavelength of maximum absorption (lambda max) of 
flupirtine was 304 nm.  
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Table 3: Standard plot data of flupirtine maleate 
S. no. Concentration (µg/ml) Absorbance 
1 0 0 
2 10 0.188 
3 20 0.386 
4 30 0.599 
5 40 0.880 
6 50 0.996 
 
 
Figure 1: Calibration curve of flupirtine 
maleate 
From the graph of absorbance vs. concentration for pure 
flupirtine it was observed that the drug obeysbeer’s law 
in concentration range of 10-50 μg/ml (r= 0.999) at 304 
nm (Table3, Figure 1). 
Solubility studies of flupirtine maleate in difrrent 
hydrotropic solvent: 
The solubility of the active pharmaceutical ingredients a 
key physicochemical factor impacting various junctures 
of drug discovery and development. A low aqueous 
solubility of a drug leads to poor therapeutic response. It 
plays a vital role in the design and development of 
different dosage forms for various routes of 
administration ranging from oral to parenteral. In the 
present case, the results of solubility studies for 
flupirtine in various hydrotropic agents are given in 
Table 4 & Fig. 2. The maximum solubility was found to 
be in a mixture of 20% niacinamide and Sodium 
benzoate. So this hydrotropic compound to be used in 
further studies. 
  
Table 4: Results of solubility studies of flupirtine maleate in various aqueous solutions of solubilizers 
S. No. Blend Blends composition (w/v) 
Solubility 
(mg/ml) 
% solubility 
1 A 10%SB + 10%NM 128.22 12.82 
2 B 10%NM + 10%FT + 10%SB 58.69 5.86 
3 C 10%SB + 10%ST 50.69 5.06 
5 E 20%NM+ 20%SB 163.86 16.38 
6 F 20%SB+ 20%ST 140.02 14.00 
7 G 20%FT+ 20%NM 150.96 15.09 
8 H 10%NM+ 5% SB+ 5%ST+ 5%FT 58.72 5.87 
9 I 20%SB+ 10%NM+ 10%SCI 130.20 13.02 
10 J 15%SB+ 15%NM 109.79 10.97 
11 K 10%SB+ 10%ST 60.96 6.09 
12 L 10%NM+ 10%SCI+10%SA 72.78 7.27 
13 M 5%NM+10%ST+5%FT 80.27 8.02 
14 N 15%NM+5%SCI+10%FT 75.56 7.55 
15 O 15%NM+15%ST 135.67 13.56 
Where SB = Sodium benzoate, NM = Niacinamide, SCI = Sodium citrate, SA=sodiumacetate ST= PEG 6000, FT= PEG 4000 
 
 
Figure 2: Graphical representation of solubility of 
flupirtine maleate in various aqueous solutions of 
solubilizers (blends) 
Drug content: 
Actual drug content of all five formulations were shown 
in (Table 5). The drug content of the prepared SDs was 
found to be in the range of 21.63 - 33.59 % indicating 
good uniformity in drug content in all the formulations. 
Table 5: Estimation drug content of solid dispersions 
of flupirtine maleate 
S.No. Solid dispersion 
Drug content (% w/v) 
Solid dispersion 
1 SDA 21.63 
2 SDB 23.86 
3 SDC 25.63 
4 SDD 33.59 
5 SDE 24.67 
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Micromeritic studies: 
Micromeritic properties of solid dispersion of a 
flupirtine maleate were studied by bulk density, tapped 
density, carr’s index, hausner ratio and angle of repose. 
These studied are done to find out the particle size of the 
drugs that has been used in the formulation. The unit of 
particle size most frequently used in micromeritic is 
micrometer also known as micron. The studied were 
determined and shown in table 6 
In Vitro dissolution studies: 
Dissolution studies were performed to compare the drug 
release from the solid dispersions, Physical mixtures to 
that of the pure drug. The dissolution test was carried 
out for a period of 60 min in water. All the experiments 
were carried out in duplicate and  best result was found 
to be in SDB the results were shown in table 7. The drug 
release profiles were shown in figure 3. 
Table 6: Results of micromeritic properties of solid 
dispersion SDA 
S.No. Parameter Result 
1 Bulk density (gm/cm
3
) 0.491 
2 Tapped density (gm/cm
3
) 0.709 
3 Compressibility index 19.26 
4 Hausner ratio 1.045 
5 Angle of repose 26.89 
 
 
Table 7: Dissolution rate studies of solid dispersion SDB, physical mixture PMB and bulk drug flupirtine 
maleate 
S.No. 
Time 
(min) 
SDB PMB Bulk drug 
% CDD % CDD % CDD 
1 0 0 0 0 
2 2 10.84 6.34 0.82 
3 5 21.6 13.08 1.09 
4 10 32.67 20.09 1.76 
5 15 43.36 27.22 3.04 
6 30 53.99 34.88 5.16 
7 45 64.63 43.05 7.84 
8 60 75.18 51.71 10.98 
% CDD= % cumulative drug dissolved 
 
 
Figure 3: Cumulative % drug dissolved v/s time plot 
of solid dispersion SDB, physical mixture PMB and 
bulk drug flupirtine maleate 
Flupirtine compatibility with excipients was studied by 
FTIR. The FTIR spectra of formulations with excipients 
reveal no interaction between drug and excipients; both 
the drug and excipients peaks were identified and 
interpreted in the spectra. The FTIR studies from the 
spectra confirmed the absence of any chemical 
interaction between the drug and excipients. The FT-IR 
spectra of drug and formulation are shown in figure 4. 
 
 
Figure 4: IR spectra of Solid dispersion (SDB) 
0 
50 
100 
0 2 5 10 15 30 45 60 
Dissolution rate 
SDB PMB  Bulk drug 
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The X-ray diffraction pattern of flupirtine exhibited 
sharp, highly intense and less diffused peaks indicating 
the crystalline nature of drug as shown in figure 5(A). 
Optimized Formulations SDB revealed a reduction in 
peak intensity when compared with XRD of plain drug 
as shown in figure 5 (C). The characteristic peaks 
identified in the drug XRD was not detected in 
formulation. Decrease in the intensities and less number 
of peaks was probably due to change in crystal habit or 
conversion to an amorphous form. Reduced crystalline 
properties when compared to pure drug could account 
for increased dissolution. 
 
 
(A) 
 
(B) 
 
(C) 
Figure 5: XRD graph of (A) Pure drug (B) Physical mixture (PMB) (C) Solid dispersion (SDB) 
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DSC of the pure drug showed a sharp peak at 180ºC. 
DSC of SDB showed peak characteristic of the drug 
with no additional peaks. From DSC, it can be 
concluded that the drug and carrier showed no 
interaction. Thermo grams are shown in figure 6. 
 
 
Figure 6: DSC graph of pure drug 
 
CONCLUSION 
The solid dispersions of flupirtine maleate were 
developed using the concept of mixed hydrotropic 
solubilization technique. Solid dispersions containing 
blend of niacinamide and sodium benzoate as water-
soluble carriers show fast release of drug as compared 
with the pure bulk drug sample and PM; the quick onset 
of action and better extent of absorption is expected 
after oral administration of these HSDs. The proposed 
techniques would be economical, convenient and safe. 
Thus, the study opens the chances of preparing solid 
dispersion of poorly water-soluble drugs. If chemical 
stability of the drug remains unaffected to open a new 
era of more stable, economic and safe products in the 
market. 
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